| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 55390-0493-01 | 55390-0493 | Etoposide | Etoposide | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Sep 28, 2001 | May 31, 2013 | No Longer Used | |
| 55390-0491-01 | 55390-0491 | Etoposide | Etoposide | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Oct 22, 2001 | Mar 31, 2012 | No Longer Used | |
| 16729-0262-31 | 16729-0262 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Aug 22, 2013 | Oct 31, 2021 | No Longer Used |
| 68001-0265-23 | 68001-0265 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Nov 14, 2013 | In Use | |
| 68001-0265-25 | 68001-0265 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Nov 14, 2013 | In Use | |
| 55390-0492-01 | 55390-0492 | Etoposide | Etoposide | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Oct 22, 2001 | Jan 31, 2013 | No Longer Used | |
| 71288-0177-50 | 71288-0177 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Feb 1, 2025 | In Use | |
| 63323-0104-05 | 63323-0104 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Jul 18, 2001 | In Use | |
| 00703-5656-01 | 00703-5656 | Etoposide | Toposar | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Aug 1, 1996 | Jan 31, 2024 | No Longer Used |
| 68001-0683-27 | 68001-0683 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Dec 1, 2025 | In Use | |
| 76128-0155-75 | 76128-0155 | Porfimer sodium | Photofrin | 75.0 mg/31.8mL | Chemotherapy | Photosensitizing Agent | Cytotoxin | Intravenous | Dec 27, 1995 | In Use | |
| 64067-0216-01 | 64067-0216 | Methoxsalen | UVADEX | 20.0 ug/mL | Chemotherapy | Photosensitizing Agent | Psoralen | Extracorporeal | Feb 25, 1999 | In Use | |
| 83616-0106-11 | 83616-0106 | Vusolimogene oderparepvec-wtpg | Tudriqev | 1000000.0 [PFU]/mL | Immunotherapy | Oncolytic Viral Therapy | GALV-GP-R, GM-CSF | INTRATUMOR | Sep 4, 2026 | In Use | |
| 83616-0107-11 | 83616-0107 | Vusolimogene oderparepvec-wtpg | Tudriqev | 10000000.0 [PFU]/mL | Immunotherapy | Oncolytic Viral Therapy | GALV-GP-R, GM-CSF | INTRATUMOR | Sep 4, 2026 | In Use | |
| 72606-0059-01 | 72606-0059 | Denosumab-bmwo | Denosumab-BMWO | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Sep 10, 2025 | In Use | |
| 00002-7190-01 | 00002-7190 | Olaratumab | Lartruvo | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | PDGFR | Intravenous | Feb 14, 2017 | Nov 27, 2020 | No Longer Used |
| 69448-0022-63 | 69448-0022 | Denosumab-desu | JUBEREQ | 70.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jul 13, 2026 | In Use | |
| 00173-0821-33 | 00173-0821 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jul 22, 2011 | Aug 31, 2017 | No Longer Used |
| 55513-0132-21 | 55513-0132 | trastuzumab-anns | Kanjinti | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jul 1, 2025 | In Use | |
| 50881-0013-03 | 50881-0013 | Tafasitamab-cxix | MONJUVI | 200.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD19 | Intravenous | Aug 5, 2020 | In Use | |
| 00069-0249-01 | 00069-0249 | Rituximab-pvvr | Ruxience | 500.0 mg/50mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan 23, 2020 | In Use | |
| 00469-3425-10 | 00469-3425 | ZOLBETUXIMAB | VYLOY | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CLDN18.2 | Intravenous | Oct 24, 2024 | In Use | |
| 82705-0010-01 | 82705-0010 | Epcoritamab-bysp | EPKINLY | 48.0 mg/.8mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Subcutaneous | May 19, 2023 | In Use | |
| 50242-0109-01 | 50242-0109 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | Jun 22, 2017 | In Use | |
| 83457-0012-10 | 83457-0012 | Denosumab | OSPOMYV | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Oct 10, 2025 | In Use |
Found 12611 results — Export these results
Home